CCDC106 Promotes the Proliferation and Invasion of Ovarian Cancer Cells by Suppressing P21 Transcription Through a P53-independent Pathway

Overview

Journal Bioengineered

Date 2022 Apr 29

PMID 35484984

Authors

Na Zhao

Chen Wang

Peng Guo

Jun Hou

Hong Yang

Ting Lan

Yehan Zhou

Jiayu Li

Ujjal K Bhawal

Yang Liu

Affiliations

Soon will be listed here.

Abstract

Ovarian cancers are the major cause of mortality for women worldwide. This study was aimed to elucidate the biological activities of CCDC106 in the proliferation and invasion of mutant p53 and of wild-type p53 ovarian cancer cells. CAOV3 (mutant p53) cells showed high expression levels of CCDC106, but it was expressed at low levels in SKOV3 (mutant p53) and in A2780 (wild-type p53) cells. The overexpression of CCDC106 promoted the expression of proliferation markers (cyclin family members), invasion and Epithelial-to-mesenchymal transition (EMT) markers (claudin-1, claudin-4, N-cadherin, snail, slug) while the knockdown of CCDC106 inhibited their expression in mutant p53 cells but not in wild-type p53 cells. Treatment with a CK2 inhibitor blocked the translocation of CCDC106 into the nuclei of mutant p53 cells. Immunoprecipitation assays confirmed that ATF4 is a potential binding partner of CCDC106. The overexpression of CCDC106 reduced p21 and p27 protein expression levels while treatment with an ATF4 siRNA rescued their expression. The overexpression of CCDC106 promoted colony formation and invasion of mutant p53 cells, which was suppressed by treatment with an ATF4 siRNA. Immunohistochemistry results showed that CCDC106 and ATF4 are expressed at high levels but p21 is expressed at low levels in FIGO III-IV stage and in mutant p53 ovarian cancer samples. A significant association between poor overall survival and high CCDC106 and ATF4 expression levels was observed in human ovarian cancer samples. In conclusion, CCDC106 promotes proliferation, invasion and EMT of mutant p53 ovarian cancer cells via the ATF4 mediated inhibition of p21.

Citing Articles

An Overview of Research Advances in Oncology Regarding the Transcription Factor ATF4.

Chen Y, Gao Q, Wang D, Zou X, Li X, Ji J Curr Drug Targets. 2024; 26(1):59-72.

PMID: 39350552 DOI: 10.2174/0113894501328461240921062056.

CCDC113 promotes colorectal cancer tumorigenesis and metastasis via TGF-β signaling pathway.

Hou C, Yang Y, Wang P, Xie H, Jin S, Zhao L Cell Death Dis. 2024; 15(9):666.

PMID: 39261464 PMC: 11390942. DOI: 10.1038/s41419-024-07036-3.

Cis- and trans-eQTL TWASs of breast and ovarian cancer identify more than 100 susceptibility genes in the BCAC and OCAC consortia.

Head S, Dezem F, Todor A, Yang J, Plummer J, Gayther S Am J Hum Genet. 2024; 111(6):1084-1099.

PMID: 38723630 PMC: 11179407. DOI: 10.1016/j.ajhg.2024.04.012.

Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.

Zhou T, Ke Z, Ma Q, Xiang J, Gao M, Huang Y Sci Rep. 2023; 13(1):21892.

PMID: 38081879 PMC: 10713525. DOI: 10.1038/s41598-023-47808-z.

- and -eQTL TWAS of breast and ovarian cancer identify more than 100 risk associated genes in the BCAC and OCAC consortia.

Head S, Dezem F, Todor A, Yang J, Plummer J, Gayther S bioRxiv. 2023; .

PMID: 38014246 PMC: 10680675. DOI: 10.1101/2023.11.09.566218.

References

Pang H, Li X, Zhao Y, Kang J, Li J, Tian W . Confirming whether novel rhein derivative 4a induces paraptosis-like cell death by endoplasmic reticulum stress in ovarian cancer cells. Eur J Pharmacol. 2020; 886:173526. DOI: 10.1016/j.ejphar.2020.173526. View

Zhou J, Qiao X, Xiao L, Sun W, Wang L, Li H . Identification and characterization of the novel protein CCDC106 that interacts with p53 and promotes its degradation. FEBS Lett. 2010; 584(6):1085-90. DOI: 10.1016/j.febslet.2010.02.031. View

Ding L, Zhang Z, Xu Y, Zhang Y . Comparative study of Her-2, p53, Ki-67 expression and clinicopathological characteristics of breast cancer in a cohort of northern China female patients. Bioengineered. 2017; 8(4):383-392. PMC: 5553327. DOI: 10.1080/21655979.2016.1235101. View

Du J, Liu H, Mao X, Qin Y, Fan C . ATF4 promotes lung cancer cell proliferation and invasion partially through regulating Wnt/β-catenin signaling. Int J Med Sci. 2021; 18(6):1442-1448. PMC: 7893563. DOI: 10.7150/ijms.43167. View

Fleury H, Malaquin N, Tu V, Gilbert S, Martinez A, Olivier M . Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence. Nat Commun. 2019; 10(1):2556. PMC: 6560032. DOI: 10.1038/s41467-019-10460-1. View

Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y . Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012; 149(6):1269-83. PMC: 3688046. DOI: 10.1016/j.cell.2012.04.026. View

Allende-Vega N, Dias S, Milne D, Meek D . Phosphorylation of the acidic domain of Mdm2 by protein kinase CK2. Mol Cell Biochem. 2005; 274(1-2):85-90. DOI: 10.1007/s11010-005-3074-4. View

Solheim O, Forsund M, Trope C, Kraggerud S, Nesland J, Davidson B . Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors. APMIS. 2017; 125(9):781-786. DOI: 10.1111/apm.12715. View

Wang W, El-Deiry W . Restoration of p53 to limit tumor growth. Curr Opin Oncol. 2007; 20(1):90-6. DOI: 10.1097/CCO.0b013e3282f31d6f. View

10.

Wang X, Sun Q . TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2016; 8(1):624-643. PMC: 5352183. DOI: 10.18632/oncotarget.13483. View

11.

Zeng X, Xie H, Yuan J, Jiang X, Yong J, Zeng D . M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. Cancer Biol Ther. 2019; 20(7):956-966. PMC: 6606001. DOI: 10.1080/15384047.2018.1564567. View

12.

Ning Y, Wang C, Liu X, Du Y, Liu S, Liu K . CK2-mediated CCDC106 phosphorylation is required for p53 degradation in cancer progression. J Exp Clin Cancer Res. 2019; 38(1):131. PMC: 6423756. DOI: 10.1186/s13046-019-1137-8. View

13.

Hollstein M, Rice K, Greenblatt M, Soussi T, Fuchs R, Sorlie T . Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994; 22(17):3551-5. PMC: 308317. View

14.

Abida W, Nikolaev A, Zhao W, Zhang W, Gu W . FBXO11 promotes the Neddylation of p53 and inhibits its transcriptional activity. J Biol Chem. 2006; 282(3):1797-804. PMC: 3690493. DOI: 10.1074/jbc.M609001200. View

15.

Zhang Z, Yin J, Zhang C, Liang N, Bai N, Chang A . Activating transcription factor 4 increases chemotherapeutics resistance of human hepatocellular carcinoma. Cancer Biol Ther. 2012; 13(6):435-42. DOI: 10.4161/cbt.19295. View

16.

Bali A, OBrien P, Edwards L, Sutherland R, Hacker N, Henshall S . Cyclin D1, p53, and p21Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res. 2004; 10(15):5168-77. DOI: 10.1158/1078-0432.CCR-03-0751. View

17.

Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck F, Goehler H . A human protein-protein interaction network: a resource for annotating the proteome. Cell. 2005; 122(6):957-68. DOI: 10.1016/j.cell.2005.08.029. View

18.

. Correction: p53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis. Cancer Res. 2016; 76(6):1668. DOI: 10.1158/0008-5472.CAN-16-0231. View

19.

Wang M, Lu Y, Wang H, Wu Y, Xu X, Li Y . High ATF4 Expression Is Associated With Poor Prognosis, Amino Acid Metabolism, and Autophagy in Gastric Cancer. Front Oncol. 2022; 11:740120. PMC: 8718699. DOI: 10.3389/fonc.2021.740120. View

20.

Schmidt J, Danielson K, Duffner E, Radecki S, Walker G, Shelton A . Regulation of the oncogenic phenotype by the nuclear body protein ZC3H8. BMC Cancer. 2018; 18(1):759. PMC: 6057032. DOI: 10.1186/s12885-018-4674-1. View